col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

Springer Science and Business Media LLC: Leukemia
  original article Date Title Authors   All Authors
1 [GO] 2021―Jun―28 Correction: Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, Francesco Landi, et al. (+16)
2 [GO] 2021―Jun―23 An evidence that SARS-Cov-2/COVID-19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome-dependent manner Magdalena Kucia, Janina Ratajczak, Kamila Bujko, Mateusz Adamiak, Andrzej Ciechanowicz, Vira Chumak, et al. (+2)
3 [GO] 2021―Jun―02 COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey Per Ljungman, Rafael de la Camara, Malgorzata Mikulska, Gloria Tridello, Beatriz Aguado, Mohsen Al Zahrani, et al. (+24)
4 [GO] 2021―May―24 Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19 Giuseppe Gritti, Federico Raimondi, Barbara Bottazzi, Diego Ripamonti, Ivano Riva, Francesco Landi, et al. (+16)
5 [GO] 2021―May―22 Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms Patrick Harrington, Hugues de Lavallade, Katie J. Doores, Amy O’Reilly, Jeffrey Seow, Carl Graham, et al. (+14)
6 [GO] 2021―May―18 Seroconversion and dynamics of the anti-SARS-CoV-2 antibody response related to a hospital COVID-19 outbreak among pediatric oncology patients Nikolay Mayanskiy, Polina Luchkina, Natalia Fedorova, Yuri Lebedin, Natalia Ponomareva
7 [GO] 2021―May―17 Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19) Chong-xiang Chen, Fang Hu, Jin Wei, Le-tao Yuan, Tian-meng Wen, Robert Peter Gale, Yang Liang
8 [GO] 2021―May―14 JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Chong-xiang Chen, Jiao-jiao Wang, Huan Li, Le-tao Yuan, Robert Peter Gale, Yang Liang
9 [GO] 2021―May―13 COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia Lindsey E. Roeker, David A. Knorr, Meghan C. Thompson, Mariely Nivar, Sonia Lebowitz, Nicole Peters, et al. (+12)
10 [GO] 2021―May―04 Hairy cell leukemia and COVID-19 adaptation of treatment guidelines Michael Grever, Leslie Andritsos, Versha Banerji, Jacqueline C. Barrientos, Seema Bhat, James S. Blachly, et al. (+33)
11 [GO] 2021―Mar―17 Ruxolitinib withdrawal due to the COVID-19 Marko Lucijanic, Rajko Kusec
12 [GO] 2021―Feb―25 Response to: Ruxolitinib withdrawal due to the COVID-19 Tiziano Barbui, Alessandra Carobbio
13 [GO] 2021―Feb―20 Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection Philipp A. Reuken, Andreas Stallmach, Mathias W. Pletz, Christian Brandt, Nico Andreas, Sabine Hahnfeld, et al. (+4)
14 [GO] 2021―Feb―13 Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm Richard A. Salisbury, Natalia Curto-Garcia, Jennifer O’Sullivan, Frederick Chen, Paolo Polzella, Anna L. Godfrey, et al. (+31)
15 [GO] 2021―Jan―07 High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, et al. (+45)
16 [GO] 2020―Dec―09 SARS-CoV-2 antibody responses in patients with acute leukaemia J. O’Nions, L. Muir, J. Zheng, C. Rees-Spear, A. Rosa, C. Roustan, et al. (+6)
17 [GO] 2020―Nov―10 Low-dose ruxolitinib plus steroid in severe SARS-CoV-2 pneumonia A. D’Alessio, P. Del Poggio, F. Bracchi, G. Cesana, N. Sertori, D. Di Mauro, et al. (+7)
18 [GO] 2020―Oct―26 COVID-19 and myeloproliferative neoplasms: some considerations Baransel Kamaz, Ann Mullally
19 [GO] 2020―Sep―02 The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 Alessandro Gozzetti, Enrico Capochiani, Monica Bocchia
20 [GO] 2020―Aug―25 COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey Massimo Breccia, Alfonso Piciocchi, Valerio De Stefano, Guido Finazzi, Alessandra Iurlo, Paola Fazi, et al. (+8)
21 [GO] 2020―Aug―19 Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study Alessandro M. Vannucchi, Benedetta Sordi, Alessandro Morettini, Carlo Nozzoli, Loredana Poggesi, Filippo Pieralli, et al. (+22)
22 [GO] 2020―Aug―14 COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter Ankur Varma, Satyajit Kosuri, Celalettin Ustun, Uroosa Ibrahim, Jonathan Moreira, Michael R. Bishop, et al. (+6)
23 [GO] 2020―Aug―07 Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time Chiara Cattaneo, Chiara Pagani, Valeria Cancelli, Luisa Imberti, Aldo M. Roccaro, Luigi D. Notarangelo, Giuseppe Rossi
24 [GO] 2020―Aug―04 Reply to “CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report” Analysis of six hematological centers in Lombardy Gianluigi Reda, Alessandro Noto, Ramona Cassin, Giulia Zamprogna, Chiara Borella, Lydia Scarfò, et al. (+5)
25 [GO] 2020―Jul―20 Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission Qiubai Li, Lei Chen, Qin Li, Wenjuan He, Jianming Yu, Li Chen, et al. (+13)
26 [GO] 2020―Jul―09 COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta, Candida Vitale, et al. (+76)
27 [GO] 2020―Jul―08 Prevalence of COVID-19 diagnosis in Dutch CML patients during the 2020 SARS-CoV2 pandemic. A prospective cohort study Geneviève I. C. G. Ector, Elisabeth G. W. Huijskens, Nicole M. A. Blijlevens, Peter E. Westerweel
28 [GO] 2020―Jul―08 Clinical characteristics and outcome of SARS-CoV-2-infected patients with haematological diseases: a retrospective case study in four hospitals in Italy, Spain and the Netherlands Jaap van Doesum, Anabelle Chinea, Maria Pagliaro, Maria Cristina Pasquini, Tom van Meerten, Martijn Bakker, Emanuele Ammatuna
29 [GO] 2020―Jul―03 How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey Francesca Palandri, Alfonso Piciocchi, Valerio De Stefano, Massimo Breccia, Guido Finazzi, Alessandra Iurlo, et al. (+8)
30 [GO] 2020―Jun―29 COVID-19 among fit patients with CLL treated with venetoclax-based combinations Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, Anna Maria Fink, Sandra Robrecht, Julia von Tresckow, et al. (+16)
31 [GO] 2020―Jun―19 Impact of Covid-19 on the treatment of acute myeloid leukemia Felicetto Ferrara, Patrizia Zappasodi, Elisa Roncoroni, Erika Borlenghi, Giuseppe Rossi
32 [GO] 2020―Jun―18 Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey Massimo Breccia, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio, Fausto Castagnetti, Carmen Fava, et al. (+13)
33 [GO] 2020―Jun―18 Regional BCG vaccination policy in former East- and West Germany may impact on both severity of SARS-CoV-2 and incidence of childhood leukemia Julia Hauer, Ute Fischer, Franziska Auer, Arndt Borkhardt
34 [GO] 2020―Jun―17 Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS) Andreas Neubauer, Thomas Wiesmann, Claus F. Vogelmeier, Elisabeth Mack, Chrysanthi Skevaki, Christine Gaik, et al. (+7)
35 [GO] 2020―Jun―16 Risk factors for death in 1859 subjects with COVID-19 Lei Chen, Jianming Yu, Wenjuan He, Li Chen, Guolin Yuan, Fang Dong, et al. (+15)
36 [GO] 2020―Jun―11 Hematological features of persons with COVID-19 Qiubai Li, Yulin Cao, Lei Chen, Di Wu, Jianming Yu, Hongxiang Wang, et al. (+13)
37 [GO] 2020―Jun―11 Holding CoVID in check through JAK? The MPN-approved compound ruxolitinib as a potential strategy to treat SARS-CoV-2 induced systemic hyperinflammation F. Heidel, A. Hochhaus
38 [GO] 2020―Jun―09 The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation F. La Rosée, H. C. Bremer, I. Gehrke, A. Kehr, A. Hochhaus, S. Birndt, et al. (+5)
39 [GO] 2020―Jun―01 Multiple myeloma and COVID-19 Binod Dhakal, Anita D’Souza, Saurabh Chhabra, Parameswaran Hari
40 [GO] 2020―Jun―01 SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine “storm” and risk factor for damage of hematopoietic stem cells Mariusz Z. Ratajczak, Magda Kucia
41 [GO] 2020―May―22 Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN) Evangelos Terpos, Monika Engelhardt, Gordon Cook, Francesca Gay, Maria-Victoria Mateos, Ioannis Ntanasis-Stathopoulos, et al. (+12)
42 [GO] 2020―May―19 CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report Tycho Baumann, Julio Delgado, Emili Montserrat
43 [GO] 2020―May―05 Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis Huan Li, Chongxiang Chen, Fang Hu, Jiaojiao Wang, Qingyu Zhao, Robert Peter Gale, Yang Liang
44 [GO] 2020―May―01 Frequently asked questions regarding SARS-CoV-2 in cancer patients-recommendations for clinicians caring for patients with malignant diseases Marie von Lilienfeld-Toal, Jörg Janne Vehreschild, Oliver Cornely, Livio Pagano, Francesca Compagno, Hans H. Hirsch
45 [GO] 2020―Apr―24 COVID-19 in persons with haematological cancers Wenjuan He, Lei Chen, Li Chen, Guolin Yuan, Yun Fang, Wenlan Chen, et al. (+9)


[de][en]

Last change 2021―Jun―30 20:09:44 UTC

© Daten-Quadrat 2021       Done in 0.014 sec